Immuneering Corporation

NASDAQ:IMRX

Biotechnology

Healthcare
$3.50 -0.14%

-$0.01 today

Market cap
$226.67M
Beta
0.38
P/E (TTM)
-3.6
EPS (TTM)
-$1.24
52W Low $2.29High $10.08

Volume 0.73M

Average 1.38M

IMRX Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Immuneering CorporationNASDAQ: IMRX

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue remains negative

Q1 FY2026 cost of revenue was $180.48K, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $793.21K. Over 3 fiscal years it compounded at +64.1% a year.

Context

  • Cost of revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near $180.48K or moves back toward the trailing-twelve-month quarterly average of $198.3K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$180.48K-70.5% QoQ
Last fiscal yearDec 2025
$698.89K— YoY
LTMMar 2026
$793.21K+354.2% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR+64.1%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
698.89K USD
Year-over-year change
—
4-year CAGR
-11.8%

Cost of Revenue vs competitors

How IMRX compares with its peers on the latest reported figures

  • IMRX's LTM Mar 2026 cost of revenue of $793.21K is the 8th highest of the 11 companies compared; the peer median is $5.16M.
  • Its year-over-year change of +354.2% is the highest of 6, against a peer median of -43.5%.
  • Over three fiscal years its annual growth of +64.1% compares with a peer median of +11.3%.
IMRX Competitors Peer median
Cost of Revenue for IMRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$40.05M ——698.0%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$21.94M ——77.7%
HUMAHumacyte, Inc.LTM Mar 2026$17.11M +85.4%+27.3%848.5%
ASMBAssembly Biosciences, Inc.LTM Mar 2026$16.18M -62.1%-87.7%22.8%
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$6.32M -43.5%+23.7%—
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$4M ——8.8%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$1.21M ——1.7%
IMRXImmuneering CorporationLTM Mar 2026$793.21K +354.2%+64.1%—
PYXSPyxis Oncology, Inc.LTM Mar 2026$27K ——0.2%
ZURAZura Bio LimitedLTM Mar 2026$16K +220.0%——
TNYATenaya Therapeutics, Inc.LTM Mar 2026-$101K -104.8%-1.1%44.9%
Peer median (excluding IMRX) $5.16M-43.5%+11.3%33.8%

Competitors are the stored peer set for IMRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.08M316.95K000
Cost of Revenue1.15M158.12K00698.89K
Gross Profit926.89K158.83K00(698.89K)
Gross Margin44.6%50.1%———
Research & Development26.54M36.27M41.62M47.96M42.05M
Selling, General & Admin8.27M15.61M16.76M16.08M17.3M
Operating Expenses34.81M51.9M58.41M64.07M58.68M
Depreciation & Amortization159.07K277.25K352.08K385.07K698.89K
EBITDA(33.68M)(51.47M)(58.06M)(63.69M)(55.33M)
EBITDA Margin-1619.5%-16238.4%———
Operating Income(33.89M)(51.74M)(58.41M)(64.07M)(59.38M)
Operating Margin-1629.2%-16325.8%———
Interest Income169.9K1.01M3.61M2.59M3.04M
Interest Expense00000
Other Income / Expenses42.83K1.23M4.94M3.03M3.35M
Income Before Tax(33.84M)(50.51M)(53.47M)(61.04M)(56.02M)
Pre-Tax Margin-1627.1%-15937.4%———
Income Tax Expense(307.49K)0000
Net Income(33.54M)(50.51M)(53.47M)(61.04M)(56.02M)
Net Margin-1612.3%-15937.3%———
EPS (Basic)(1.27)(1.87)(1.88)(2.04)(1.27)
EPS (Diluted)(1.27)(1.87)(1.88)(2.04)(1.27)
Weighted Avg Shares26.32M26.39M28.42M29.98M44.01M
Weighted Avg Shares (Diluted)26.32M26.39M28.42M29.98M44.01M

Immuneering Corporation

NASDAQ:IMRX

Intrinsic Alpha fair value

Locked

Current Price

$3.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.